Cipla acknowledged at UN General Assembly, as the leading partner in the fight against non-communicable diseases

Cipla, under innovative public-private partnerships, works on a mission mode in different program components.

0
Cipla acknowledged at UN General Assembly, as the leading partner in the fight against non-communicable diseases

Mumbai: Nicotine replacement Therapy, advanced by Nicotex has been powering the quit-smoking mission across our country. Recognizing Cipla’s active and consistent role in tobacco cessation in India, the Director-General of WHO Tedros Adhanom Ghebreyesus commended Cipla as a leading partner in the prevention of NCDs (Non-communicable diseases). The announcement was made at the recent global UN conference on Meeting the Noncommunicable Diseases and Mental Health-related SDG Target around World Lung Day.

The community-level outreach interventions, like those in Maharashtra, Madhya Pradesh, Goa and Karnataka are implemented under NCDC (Non-Communicable Disease Control) programs. Cipla, under innovative public-private partnerships, works on a mission mode in different program components. Counseling, integrating tobacco cessation at primary health care, intersectoral linkages, sensitizing youth, training of trainers, and capacity building of health care professionals and workers are some of its key focus areas. It channelizes efforts towards educating and aiding people to quit smoking thus protecting them from the detrimental effects of the same. Nicotex has successfully managed to incite the adoption and integration of NRT therapies among 8 lakh smokers in the last year.

Also Read: What is the recent scenario of Morbidity patterns among Geriatric population?

Nicotex which has been the reliable change agent for tobacco users has been actively supported by Indian Dental Association (IDA), private practitioners, and dental colleges where tobacco intervention programs are undertaken. The public health program of tobacco cessation, under the aegis of the National Health Mission, has the potential to transform India – social, economic, and environment. Nicotex, Made in India, has spurred successful last-mile public health interventions in India, now catching global attention as “good practice”.

Commenting on this recent announcement, Shivam Puri, CEO – Cipla Health Ltd says, “Globally, WHO and Cipla Health Ltd. have partnered in various programs, including the donation of Nicotex patches and gums in Timor Leste where it has played a crucial role in limiting the use of tobacco through the use of acceptable alternatives.

The high consumption of tobacco in its various forms should be a matter of concern for all of us. We at Cipla Health have always been conscious of our responsibility in this area and realize that we will only be able to fight this global menace through coalition, cognizance, and care. Nicotex’s key driving force has always been to educate people about the downside of this habit and help them eventually part ways with it. Our efforts have been consistent since day one and we feel honored to be recognized by World Health Organisation although we have a long way to go.”

WHO has confirmed that smokers are likely to be more susceptible to serious COVID-19 related conditions, including fatality. Cipla Health is at the forefront by working closely with various government bodies and also deploying its smoking cessation products under Nicotex as a significant step in reducing the pandemic’s debilitating burden on national socio-economic status.

Estimates suggest that the NCDs alone in India account for an economic load of 5–10% of GDP. Coupled with the pandemic, it poses a serious threat to the country’s development.

About Cipla Health Limited

Cipla Health Ltd. (CHL), the consumer healthcare subsidiary of Cipla, was founded in 2015 with a vision to spearhead consumer healthcare in India. With an existing wide customer base, the company believes in consistent innovation and aims to make a difference in the consumer’s everyday life. CHL offers a folio of diverse brands, distilled out of an entrepreneurial journey from conception, the process to delivery — Nicotex, Cofsils, Prolyte ORS, MamaXpert, Maxirich, Naselin, Omnigel, Ciphands, and Clocip. In line with CHL’s mission of improving consumer lives, that Nicotex, the flagship brand of Cipla Health, is a friend to smokers in their tough journey of quitting smoking, Nicotex offers a range of products (Gums, lozenges, and patches), which helps one quit smoking using the proven principle of Nicotine replacement therapy. Nicotex is built on the vision of making India smoking-free and proud to be the No. 1 Doctor recommended brand in its category.

Summary
Article Name
Cipla acknowledged at UN General Assembly, as the leading partner in the fight against non-communicable diseases
Description
Cipla, under innovative public-private partnerships, works on a mission mode in different program components.
Author
Publisher Name
THE POLICY TIMES
Publisher Logo